Logo

Sequenom Shares Slide on Nasdaq Delisting Warning

Sep 20, 2005

NEW YORK, Sept. 20 (GenomeWeb News) - Shares of Sequenom's stock are down 4.88 percent, or $.04, at $.78 today following news this morning that the company has received a delisting warning letter from the Nasdaq exchange.

 

Sequenom received the letter from Nasdaq's listing qualifications department because the company's shares do not comply with Nasdaq's $1 minimum bid price requirement.

 

Sequenom now has 180 days, or until March 15, 2006, to regain compliance by closing at or above $1 per share for at least 10 consecutive business days. If the company does not regain compliance by this deadline, its common stock could be delisted from the exchange.

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.